These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8042863)

  • 1. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy.
    Janssen HL; Kerhof-Los CJ; Heijtink RA; Schalm SW
    Antiviral Res; 1994 Apr; 23(3-4):251-7. PubMed ID: 8042863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High rates of HBsAg loss and seroconversion result from prolonged course of pegasys treatment].
    Li MH; Xie Y; Lu Y; Qiu GH; Liu F; Li XH; Zhao H; Song SJ; Guan XP; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):182-5. PubMed ID: 21586235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of hepatitis B viral loads and viral antigen levels in child-bearing age women with and without pregnancy.
    Xu C; Liu J; Liu L; Bi Y; Xu B; Chen J; Xu B; Chen T; Hu Y; Zhou YH
    BMC Pregnancy Childbirth; 2018 Jul; 18(1):292. PubMed ID: 29980185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of quantitative measurement of HBeAg and HBsAg before interferon-alpha treatment of chronic hepatitis B in children.
    Burczynska B; Madalinski K; Pawlowska J; Woynarowski M; Socha J; Gerlich WH; Willems WR; Wozniewicz B; Stachowski J
    J Hepatol; 1994 Dec; 21(6):1097-102. PubMed ID: 7699234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
    Wang ML; Liao J; Wei B; Zhang DM; He M; Tao MC; Chen EQ; Tang H
    Infect Dis (Lond); 2018 Jul; 50(7):522-530. PubMed ID: 29463147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
    Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
    Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H; Yang RF; Wei L
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B.
    Loriot MA; Marcellin P; Bismuth E; Martinot-Peignoux M; Boyer N; Degott C; Erlinger S; Benhamou JP
    Hepatology; 1992 Jan; 15(1):32-6. PubMed ID: 1727796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corticosteroids: short- and long-term follow-up.
    Zavaglia C; Bottelli R; Bellati G; Asti L; Mondazzi L; Iamoni G; Zanetti A; Tanzi E; Fesce E; Gelosa F; Maggi G; Ideo G
    Ital J Gastroenterol; 1996; 28(6):324-31. PubMed ID: 8891847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
    Lee MH; Lee DM; Kim SS; Cheong JY; Cho SW
    J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation between serum HBV DNA level and HBsAg titer in HBeAg-positive pregnant women and impact of genomic variability of hepatitis B virus pre S/S regions on their correlations].
    Zhang X; Yan L; Lu Y; Wei KP; Liu ZX; Xiao YW; Ding F; Zhuang H; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2018 Aug; 26(8):579-584. PubMed ID: 30317788
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
    Niederau C; Heintges T; Lange S; Goldmann G; Niederau CM; Mohr L; Häussinger D
    N Engl J Med; 1996 May; 334(22):1422-7. PubMed ID: 8618580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters.
    Tseng TC; Liu CJ; Yang WT; Chen CL; Yang HC; Su TH; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1242-9. PubMed ID: 24384028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.